Gemcitabine
别名: LY-188011, NSC 613327
中文名称:吉西他滨
目录号:S1714 Purity: 99.98%
此产品请避光密封保存。
Gemcitabine是核酸合成抑制剂,是有效、特异的脱氧胞苷类似物,用于化疗。Gemcitabine可诱导有效的p53依赖的凋亡。
CAS: 95058-81-4
客户使用Selleck的Gemcitabine发表文献266篇
- Cancer Discov, 2024 10.1158/2159-8290.CD-24-0887
- Drug Resist Updat, 2024 74:101079
- Nat Cancer, 2023 4(1):62-80
- Cancer Cell, 2022 40(9):957-972.e10
- Cancer Cell, 2022 40(9):1044-1059.e8
- Mol Cancer, 2022 21(1):112
- Mol Cancer, 2021 20(1):97
- Immunity, 2020 52(2):357-373
- J Hematol Oncol, 2020 1;13(1):40
- Cancer Discov, 2020 CD-20-0706
- Nat Med, 2019 25(5):838-849
- Adv Mater, 2018 30(43):e1801621
- Cancer Discov, 2018 8(11):1404-1421
- Nature, 2017 552(7683):116-120
- Mol Cancer, 2017 16(1):22
- Nat Commun, 2024 15(1):1287
- J Immunother Cancer, 2024 12(3)e008431
- J Adv Res, 2024 S2090-1232(24)00413-2
- Cancer Lett, 2024 602:217197
- Cancer Lett, 2024 598:217109
- Cell Death Dis, 2024 15(9):657
- Cell Death Dis, 2024 15(3):237
- Cell Death Dis, 2024 15(3):187
- Cell Commun Signal, 2024 22(1):375
- Oncogene, 2024 10.1038/s41388-024-03143-9
- Blood Adv, 2024 8(20):5315-5329
- Genes Dis, 2024 11(1):430-448
- Biochem Pharmacol, 2024 223:116125
- iScience, 2024 27(1):108667
- Int J Mol Sci, 2024 25(13)7438
- Biomolecules, 2024 14(9)1178
- Biol Direct, 2024 19(1):74
- Neoplasia, 2024 47:100951
- Sci Rep, 2024 14(1):22619
- Sci Rep, 2024 14(1):8389
- J Liposome Res, 2024 1-11.
- World J Gastroenterol, 2024 30(7):714-727
- bioRxiv, 2024 2024.04.25.591092
- Nucleic Acids Res, 2023 10.1093/nar/gkad973
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101277
- Cell Death Dis, 2023 10.1038/s41419-023-06244-7
- Cell Death Dis, 2023 14(4):246
- Cell Death Dis, 2023 14(4):295
- Cell Rep, 2023 42(9):113146
- Elife, 2023 12e83867
- J Transl Med, 2023 21(1):730
- Cell Death Discov, 2023 9(1):262
- Cell Death Discov, 2023 9(1):214
- iScience, 2023 26(1):105723
- iScience, 2023 26(8):107408
- Front Pharmacol, 2023 14:1189245
- J Virol, 2023 97(9):e0100523
- Cancers -Basel), 2023 15(19)4772
- Stem Cells Int, 2023 2023:7367854
- ACS Omega, 2023 8(20):17552-17562
- PLoS One, 2023 10.1371/journal.pone.0294065
- Technol Cancer Res Treat, 2023 22:15330338231202307
- bioRxiv, 2023 2023.01.09.523344
- J Exp Clin Cancer Res, 2022 41(1):274
- J Exp Clin Cancer Res, 2022 41(1):331
- J Exp Clin Cancer Res, 2022 41(1):312
- Cell Death Dis, 2022 13-9:799
- Cell Death Dis, 2022 13(5):497
- Cell Prolif, 2022 10.1111/cpr.13237
- Oncogene, 2022 41(19):2719-2733
- JCI Insight, 2022 7(22e158060)
- NPJ Precis Oncol, 2022 6(1):75
- NPJ Precis Oncol, 2022 6(1:81)
- Cell Biosci, 2022 12(1):195
- Front Immunol, 2022 13:943066
- Cell Biol Toxicol, 2022 10.1007/s10565-022-09746-w
- NPJ Breast Cancer, 2022 8(1):44
- iScience, 2022 25(10):105182
- Cancer Cell Int, 2022 22(1):250
- Biochem Pharmacol, 2022 203:115166
- Mol Ther Oncolytics, 2022 24:59-76
- Mol Cancer Ther, 2022 21(2):347-358
- Front Pharmacol, 2022 13:1032975
- Front Pharmacol, 2022 13:903210
- Front Pharmacol, 2022 13:895744
- Front Pharmacol, 2022 13:924523
- Int J Mol Sci, 2022 23(10)5532
- Oncotarget, 2022 13:1122-1135
- Aging (Albany NY), 2022 14(19):7941-7958
- Cancers (Basel), 2022 14(19)4727
- Cancers (Basel), 2022 14(8)1968
- J Pers Med, 2022 12(2)258
- Front Oncol, 2022 12:1021632
- Front Oncol, 2022 12:830873
- Biomedicines, 2022 10(5)1162
- Mol Carcinog, 2022 10.1002/mc.23401
- Dis Model Mech, 2022 dmm.049109
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- J Cancer, 2022 13(15):3660-3673
- J Cancer, 2022 13(4):1103-1118
- PLoS One, 2022 17(4):e0266476
- Dis Markers, 2022 2022:5286820
- Hematol Oncol, 2022 10.1002/hon.3007
- Nat Commun, 2021 12(1):1602
- Cell Death Differ, 2021 10.1038/s41418-020-00733-4
- Cancer Res, 2021 canres.1337.2021
- Int J Biol Sci, 2021 17(7):1808-1820
- Cell Death Dis, 2021 12(8):772
- Cell Death Dis, 2021 12(1):72
- Br J Cancer, 2021 10.1038/s41416-021-01639-9
- Br J Cancer, 2021 10.1038/s41416-021-01658-6
- Cell Rep, 2021 34(10):108814
- Cell Prolif, 2021 e13031
- Oncogene, 2021 10.1038/s41388-021-01992-2
- Oxid Med Cell Longev, 2021 2021:6673828
- Mol Oncol, 2021 10.1002/1878-0261.13149
- Cancer Cell Int, 2021 21(1):646
- Mol Cancer Ther, 2021 molcanther.MCT-21-0474-A.2021
- Int J Mol Sci, 2021 22(13)6825
- Cancers (Basel), 2021 13(13)3367
- Cancers (Basel), 2021 14(1)5
- Cancers (Basel), 2021 13(17)4405
- Cancers (Basel), 2021 13(11)2539
- Cancers (Basel), 2021 13(3)527
- Front Mol Biosci, 2021 8:645365
- Neoplasia, 2021 23(7):643-652
- Front Oncol, 2021 11:750259
- Sci Rep, 2021 11(1):10181
- Immunol Lett, 2021 242:8-16
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- BMC Cancer, 2021 21(1):65
- PLoS One, 2021 16(2):e0236074
- Invest New Drugs, 2021 10.1007/s10637-021-01073-x.
- Invest New Drugs, 2021 10.1007/s10637-020-01003-3
- Chem Biol Drug Des, 2021 10.1111/cbdd.13977
- Int J Radiat Biol, 2021 1-16
- BMC Urol, 2021 21(1):96
- Transl Cancer Res, 2021 10(3):1368-1377
- Clin Cancer Drugs, 2021 8(1):50-56
- Adv Biol Regul, 2021 S2212-4926(20)30091-9
- Nat Commun, 2020 11(1):3018
- Nat Commun, 2020 12;11(1):2971
- Nat Commun, 2020 10;11(1):2935
- Nat Commun, 2020 24;11(1):1975
- Theranostics, 2020 10(9):3967-3979
- Cell Death Differ, 2020 10.1038/s41418-020-0505-4
- Clin Cancer Res, 2020 27 pii: clincanres
- Clin Cancer Res, 2020 26(5):1065-1076
- Cancer Res, 2020 80(5):1036-1048
- J Immunother Cancer, 2020 8(2)e000807
- Cell Rep, 2020 31(10):107745
- Cell Chem Biol, 2020 20;27(2):197-205.e6
- Biomed Pharmacother, 2020 16;127:110225
- Front Immunol, 2020 11:331
- Int J Mol Sci, 2020 21(23)E9034
- Am J Cancer Res, 2020 10(10):3302-3315
- J Cell Mol Med, 2020 24(1):760-771
- Am J Cancer Res, 2020 10(1):148-163
- Cancers (Basel), 2020 15;12(4) pii: E974
- Neoplasia, 2020 22(1):22-32
- J Biol Chem, 2020 1 pii: jbc
- Front Oncol, 2020 25;10:229
- Cancer Res Treat, 2020 10.4143/crt.2020.585
- Sci Rep, 2020 10(1):18489
- Mediators Inflamm, 2020 2020:8567320
- Sci Rep, 2020 15;10(1):337
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- BMC Cancer, 2020 20(1):984
- J Biochem Mol Toxicol, 2020 e22621
- Med Sci Monit, 2020 26:e922703
- Biochem Biophys Res Commun, 2020 522(4):952-959
- Oncol Lett, 2020 19(3):1999-2004
- Exp Hematol, 2020 81:32-41
- Am J Transl Res, 2020 12(6):2827-2842
- Anticancer Res, 2020 40(7):3659-3667
- Genes Chromosomes Cancer, 2020 10.1002/gcc.22884
- bioRxiv, 2020 2020/9/20.4.7.30734
- Clin Cancer Res, 2019 25(7):2290-2304
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0206
- Cancer Res, 2019 10.1158/0008-5472.CAN-18-3374
- Cancer Res, 2019 79(8):2009-2020
- J Immunother Cancer, 2019 7(1):199
- Cancer Lett, 2019 458:29-38
- Cell Death Dis, 2019 10(7):529
- Cell Rep, 2019 27(11):3331-3344
- Cell Rep, 2019 29(1):118-134
- Cell Rep, 2019 26(6):1518-1532
- Oncogene, 2019
- Biomed Pharmacother, 2019 109:563-572
- Cell Biosci, 2019 9:50
- Mol Ther Oncolytics, 2019 14:299-312
- Cancers (Basel), 2019 11(12)E2042
- Cancers (Basel), 2019 11(12)E1835
- Transl Oncol, 2019 12(10):1375-1385
- Sci Rep, 2019 9(1):16588
- Sci Rep, 2019 9(1):11153
- Sci Rep, 2019 9(1):6161
- Cancer Med, 2019 10.1002/cam4.2764
- Biosci Rep, 2019 39(8)
- Onco Targets Ther, 2019 12:4403-4413
- Exp Ther Med, 2019 17(1):817-823
- Anticancer Drugs, 2019 30(2):138-148
- Am J Transl Res, 2019 11(1):473-485
- Assay Drug Dev Technol, 2019 17(3):100-115
- SSRN, 2019 10.2139/ssrn.3387640
- Nat Commun, 2018 13;9(1):2720
- Theranostics, 2018 8(12):3366-3379
- Theranostics, 2018 8(14):3824-3840
- Clin Cancer Res, 2018 24(13):3197-3203
- J Exp Clin Cancer Res, 2018 37(1):291
- Cancer Res, 2018 78(19):5656-5667
- Oncogene, 2018 37(44):5843-5857
- Sci Signal, 2018 11(540)eaat0229
- Mol Cancer Ther, 2018 17(12):2676-2688
- Int J Mol Med, 2018 41(4):2003-2011
- Oncotarget, 2018 9(56):30773-30786
- Int J Oncol, 2018 53(1):215-224
- Mol Pharm, 2018 15(2):369-376
- Exp Cell Res, 2018 369(1):120-128
- Cancer Manag Res, 2018 10:6695-6703
- Cancer Biomark, 2018 22(1):169-174
- Oncol Lett, 2018 15(5):6107-6114
- Oncol Lett, 2018 16(5):6742-6748
- Leuk Res, 2018 64:34-41
- ACS Nano, 2017 11(10):10159-10174
- Biosens Bioelectron, 2017 91:780-787
- J Exp Clin Cancer Res, 2017 36(1):1
- J Immunother Cancer, 2017 5(1):101
- Cell Death Dis, 2017 8(10):e3129
- Cell Rep, 2017 19(1):101-113
- Int J Nanomedicine, 2017 12:7763-7776
- Mol Oncol, 2017 11(9):1130-1142
- Biofactors, 2017 43(1):63-72
- Respir Res, 2017 18(1):52
- Oncotarget, 2017 8(35):58417-58429
- Oncotarget, 2017 8(68):112636-112646
- Oncotarget, 2017 8(24):39460-39475
- Mol Cancer Res, 2017 15(7):953-964
- Viruses, 2017 9(10)
- Sci Rep, 2017 7(1):12891
- J Pharmacol Exp Ther, 2017 363(1):20-34
- Leuk Lymphoma, 2017 58(11):2705-2716
- Am J Transl Res, 2017 9(12):5507-5517
- Cancer Res, 2016 76(13):3978-88
- J Pineal Res, 2016 60(1):27-38
- Cancer Lett, 2016 377(1):25-31
- Cancer Lett, 2016 379(1):1-11
- Cell Death Dis, 2016 7:e2294
- Antiviral Res, 2016 133:23-31
- Nutrients, 2016 8(10)
- Clin Transl Immunology, 2016 5(12):e119
- PLoS One, 2016 11(6):e0158617
- Leuk Lymphoma, 2016 57(11):2644-52
- Sci Transl Med, 2015 7(284):284ra57
- Proc Natl Acad Sci USA, 2015 112(6):1839-44
- Cancer Sci, 2015 106(1):9-17
- Mol Cancer Ther, 2015
- Eur J Pharmacol, 2015 10.1016/j.ejphar.2015.03.064
- PLoS One, 2015 10(4):e0123901
- Nucleic Acids Res, 2014 42(10):6436-47
- Clin Cancer Res, 2014 20(12):3187-97
- J Immunol, 2014 192(9):4273-83
- PLoS One, 2014 9(10):e111146
- Mol Pharmacol, 2014 85(3):408-19
- Pancreas, 2014 44(1):144-151
- Freien Universit, 2014 Christian Kähler
- Cell Death Dis, 2013 4:e742
- Mol Cancer Ther, 2012 11(12):2633-43
- Sci Signal, 2011 1(4):352-65
化学信息&溶解度
分子量 | 263.2 |
分子式 | C9H11F2N3O4 |
CAS号 | 95058-81-4 |
Smiles | C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F |
储存条件(自收到货起) | 1年 4℃(避光) |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 53 mg/mL ( 201.36 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 53 mg/mL ( 201.36 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 52 mg/mL ( 197.56 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 13 mg/mL Ethanol : Insoluble DMSO : 53 mg/mL ( 201.36 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 53 mg/mL ( 201.36 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 10 mg/mL Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
Corn oil
浓度:5mg/ml
(19.00mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:2.5mg/ml
(9.50mM)
操作示例:以 1 mL 工作液为例,取50μL50mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
Corn oil
浓度:4mg/ml
(15.20mM)
操作示例:以 1 mL 工作液为例,取50μL80mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:2.65mg/ml
(10.07mM)
操作示例:以 1 mL 工作液为例,取50μL53mg/ml的澄清DMSO储备液加到 400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。